Evidence-based pharmacotherapy of treatment-resistant unipolar depression
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Treatment resistance to the antidepressive pharmacotherapy represents one of the most important clinical challenges in the pharmacological management of unipolar depression. In this review, we aimed to summarise the evidence for various pharmacological treatment options in therapy-resistant unipolar depression derived from clinical trials, systematic reviews, meta-analyses and treatment guidelines. The first measure in case of insufficient response to the initial antidepressant monotherapy contains the debarment of 'pseudo-resistance', potentially caused by inadequate dose and treatment duration of the antidepressant, insufficient plasma levels, non-compliance of the patient regarding medication intake or relevant psychiatric and/or somatic comorbidities. Applying a dose escalation of the current antidepressant cannot be generally recommended as evidence-based treatment option and the efficacy depends on the class of antidepressants. There is no compelling evidence for a switch to another, new antidepressant compound after insufficient response to a previous antidepressant. The combination of two antidepressants should be preferentially established with antidepressants characterised by different mechanisms of action (e.g. reuptake inhibitors together with presynaptic autoreceptor inhibitors). At present, the most convincing body of evidence exists for the augmentation of antidepressants with second-generation antipsychotic drugs and lithium. Hence, both strategies are consistently advised by treatment guidelines as pharmacological first-line strategy in treatment-resistant depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“In the STAR D study, a combination of citalopram with bupropion in patients after a treatment failure with citalopram monotherapy leads to a remission rate of 29.7% (Trivedi et al. 2006a).”
BackgroundInfluentialThe size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“In this trial, citalopram non-responders achieved remission rates between 17.6% and 24.8% after switching to bupropion, sertraline or venlafaxine without identifying any significant differences between the different antidepressant substances (Rush et al. 2006).”
BackgroundInfluentialMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 2×
“In the STAR D study, a combination of citalopram with bupropion in patients after a treatment failure with citalopram monotherapy leads to a remission rate of 29.7% (Trivedi et al. 2006a).”
BackgroundInfluentialLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 2×
“…especially patients with a high risk for suicidal behaviour can benefit from adjunctive lithium as the suicide rate under lithium was significantly reduced in a large number of RCTs and observational studies (Kessing et al. 2005; Cipriani et al. 2013; Rombold et al. 2014; Otuyelu et al. 2015).”
BackgroundBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 23×
“…guidelines of the international psychiatric societies, an increase of the antidepressant dose above the officially approved dose range (dose escalation) cannot be recommended as general treatment option for the management of treatment-resistant MDD (NICE 2009; APA 2010; Bauer et al. 2013b).”
BackgroundMethodResultInfluentialSouery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 4×
“Factors contributing to treatment resistance Souery et al. (2007) analysed 702 MDD patients participating in a large multicenter study of the European Group for the Study of Resistant Depression and revealed the following clinical factors that were associated with treatment resistance (defined as…”
BackgroundInfluentialSelf-citationMeyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 1×
“These findings are consistent with the [11C]DASB positron emission tomography study of Meyer et al. (2004) investigating the SERT occupancy of SSRIs/venlafaxine whereupon SERT occupancy of 80% occurs already at the minimum therapeutic doses.”
ResultFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 1×
“It should be considered that the termination of the medication with an antidepressant compound can provoke withdrawal symptoms (Fava et al. 2015) and these are often misinterpreted as adverse effects of the newly dispensed antidepressant drug hampering the possibility to assess the effectiveness of…”
BackgroundBlier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 1×
“With regard to initial combination strategies, two large RCTs should be taken into account: in the double-blind RCT of Blier et al. (2010) examining 105 MDD patients, combination treatments of mirtazapine together with fluoxetine, venlafaxine and bupropion were significantly more efficacious than…”
MethodShine, B., McKnight, R. F., Leaver, L., & Geddes, J. R. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61842-0 · Cited by 313 · cited 2×
“…a retrospective analysis of laboratory data of 4678 lithium-treated patients revealed a statistically significantly increased risk of stage three chronic kidney disease, hypothyroidism and enhanced total serum concentration compared to control subjects not treated with lithium (Shine et al. 2015).”
BackgroundAntidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Lenze, E. J., Mulsant, B. H., Blumberger, D. M., Karp, J. F., Newcomer, J. W., Anderson, S. J., Dew, M. A., Butters, M. A., Stack, J. A., Begley, A. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00308-6 · Cited by 283 · cited 1×
“The efficacy of aripiprazole especially for elderly people (>60 years) with treatment-resistant depression could be demonstrated in a double-blind RCT (n¼ 181) using venlafaxine ER as ongoing antidepressant medication (Lenze et al. 2015).”
MethodSpielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199 · cited 1×
“We found RCTs applying this study design for dose–escalation strategies with the SSRIs fluoxetine (Dornseif et al. 1989), paroxetine (Benkert et al. 1997; Ruhe et al. 2009) and sertraline (Schweizer et al. 2001; Licht & Qvitzau 2002).”
MethodThase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182 · cited 1×
“Recently published phase 3 studies suggest efficacy of the new drug application brexpiprazole in treatment-resistant MDD and the official approval for this indication is sought for this substance (Thase et al. 2015).”
BackgroundHolma, K. M., Haukka, J., Suominen, K., Valtonen, H. M., Mantere, O., Melartin, T. K., Sokero, T. P., Oquendo, M. A., & Isometsä, E. T. (2014) · Bipolar Disorders · doi:10.1111/bdi.12195 · Cited by 175 · cited 2×
“It is estimated that up to 10% of the patients attempt suicide (Holma et al. 2014).”
BackgroundBarbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143 · cited 1×
“Montgomery et al. (2014) compared in a prospective, randomised, double-blind trial a switch to vortioxetine on the one hand and agomelatine on the other hand in depressive patients with inadequate response to prior SSRI/SNRI monotherapy and revealed a significant superiority of vortioxetine over…”
ResultRuhé, H. G., Booij, J., Weert, H. C. V., Reitsma, J. B., Fransen, E. J. F., Michel, M. C., & Schene, A. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.148 · Cited by 73 · cited 3×
“Ruhe et al. (2009) examined in their paroxetine study additionally to the clinical response the serotonin transporter (SERT) occupancy by SPECT measurements.”
BackgroundMethod
Cited by
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Self-citationBartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Souery, D., Mendlewicz, J., Zohar, J., Montgomery, S., et al. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1635270 · Cited by 152
“2018) representing an essential therapeutic fundament as it is known from other diseases such as arterial hypertension (Kranz and Kasper 2019), up to 60% of MDD patients do not sufficiently respond to an initial antidepressant treatment (Souery et al. 1999, 2006; Kasper 2014; Dold and Kasper 2017).”
BackgroundSelf-citationKautzky, A., Dold, M., Bartova, L., Spies, M., Kranz, G. S., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Fabbri, C., et al. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12959 · Cited by 148
“Based on these shortcomings, research focused on predictive signatures of treatment resistant depression (TRD) for several decades (4, 5).”
BackgroundSelf-citationDold, M., Bartova, L., Souery, D., Mendlewicz, J., Serretti, A., Porcelli, S., Zohar, J., Montgomery, S., & Kasper, S. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.02.020 · Cited by 131
Self-citationvan Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
“Clinical reviews suggest a prevailing inclination to manage TRD (solely) by pharmacotherapy or other somatic treatments while scarcely mentioning studies into psychotherapy for TRD with little or no discussion of the findings and prospects (e.g. Carvalho et al., 2014; Dold and Kasper, 2016).”
Background
Metadata
- Authors
- Dold, M., & Kasper, S.
- Venue
- International Journal of Psychiatry in Clinical Practice
- Publisher
- Informa UK Limited
- Published
- 2016-11-16
- Volume
- 21
- Issue
- 1
- Pages
- 13-23
- ISSN
- 1365-1501 (ISSN-L)
- 1471-1788
- OpenAlex
- W2554788508
- Cited by
- 118
- References
- 23
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.